Purpose: Metastatic prostate cancer (mPC) imposes a significant clinical and economic burden across Latin America, where pharmacoepidemiological data remain scarce. In Colombia, although prostate cancer is well-documented, data specific to metastatic disease are limited, hindering effective public health planning and equitable resource allocation. This study aims to characterize the epidemiological trends of mPC in Colombia between 2014 and 2023, using integrated national databases to support pharmacoepidemiologic surveillance and inform future therapeutic and policy strategies. Methods: A retrospective, descriptive pharmacoepidemiologic study was conducted using national data from SISPRO (health services utilization), SICC (cancer registry), CAC (health benefit plans), and DANE (vital statistics). Records of men aged 18 and older diagnosed with prostate cancer between 2014 and 2023 were analyzed. Variables assessed included prevalence, incidence, and mortality, as well as demographic characteristics (age, region, ethnicity) and clinical classification (castration-sensitive vs. castration-resistant). Results: A total of 29,182 mPC patients were identified between 2014 and 2023. The annual prevalence increased from 6.5 to 22.3 cases per 100,000 men and incidence nearly doubled. The Caribbean region reported 38.9% of the cases. No substantial differences in age or ethnicity were found compared to general prostate cancer cases. Most cases were castration-sensitive (95%), although castration-resistant cases considerably increased. Conclusion: This study illustrates the growing burden of mPC in Colombia and hightlights the value of leveraging national health information systems for pharmacoepidemiologic insights. Regional disparities underscore the need for targeted policy responses. Improved real-world data integration can enhance monitoring, support drug utilization studies, and inform public health strategies.